Ely Benaim
Keine laufenden Positionen mehr
Vermögen: 449 675 $ am 31.03.2024
Profil
Ely Benaim ist Chief Medical Officer bei NovoCure Ltd. In der Vergangenheit hatte Dr. Benaim die Position des Vice President-Clinical Affairs bei Sangamo Therapeutics, Inc. inne, Chief Medical Officer & SVP-Regulatory Affairs bei Berg Pharma LLC, Senior Director-Clinical Research bei Millennium Pharmaceuticals, Inc, Chief Medical Officer von Rexahn Pharmaceuticals, Inc, Senior Director-Global Oncology bei Salmedix, Inc. und Assistenzprofessor an der University of Tennessee. Dr. Benaim erhielt einen Doktortitel von der Central University of Venezuela.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NOVOCURE LTD.
0,03% | 06.01.2023 | 28 770 ( 0,03% ) | 449 675 $ | 31.03.2024 |
Ehemalige bekannte Positionen von Ely Benaim
| Unternehmen | Position | Ende |
|---|---|---|
| NOVOCURE LIMITED | Chief Tech/Sci/R&D Officer | 17.01.2023 |
| REXAHN PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31.03.2019 |
| Berg Pharma LLC | Chief Tech/Sci/R&D Officer | 01.01.2015 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01.01.2013 |
| SANGAMO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.01.2010 |
Ausbildung von Ely Benaim
| Central University of Venezuela | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| NOVOCURE LIMITED | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Salmedix, Inc.
 Salmedix, Inc. Pharmaceuticals: MajorHealth Technology Salmedix, Inc. develops oncology and small molecule drugs to treat hematological malignancies. The company's product, Treanda, is currently in Phase II clinical trials in the United States and Canada for the treatment of indolent (slowly progressing) non-Hodgkin's lymphoma. It was founded in 2000 and is located in San Diego, CA. | Health Technology |
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
| Berg Pharma LLC |
